noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Kirkland & Ellis LLP

Private Equity/M&A Partner Adam Prince Joins Kirkland & Ellis
Oakland University

Natalie Ishioka named Student of the Year by the Great Lakes Affiliate[...]
ImmuCell Corporation

2025 Form 10-K (proofs 0000811641 118730 ALL DOCS clean pn120)

Healthcare

Pappas Capital LLC

06/20/2012 | Press release | Archived content

Liquidia Announces Product Development Collaboration with GlaxoSm...

News | 06. 20. 2012

Liquidia Technologies

RESEARCH TRIANGLE PARK, NC- June 20, 2012 -‐ Liquidia Technologies today announced the initiation of a broad, multi-‐year collaboration with GlaxoSmithKline (GSK), which has acquired exclusive rights to research and develop certain vaccine and inhaled product candidates using the company's proprietary PRINT® (Particle Replication In Non-‐Wetting Templates) technology. Liquidia's PRINT technology is a powerful and versatile nanoparticle technology product development and manufacturing platform that is changing the way companies engineer healthcare products.

Pappas Capital LLC published this content on June 20, 2012, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 22, 2026 at 10:07 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back

View original format